A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter ...
Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital in Sweden have determined how children's ...
New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...
T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...
AstraZeneca’s Calquence plus chemoimmunotherapy approved in US for patients with previously untreated mantle cell lymphoma: Cambridge, UK Monday, January 20, 2025, 09:00 Hrs [IS ...
InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,295 ...
Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.
AstraZeneca's Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreate ...
Cambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in ...
The drugs treat prostate, breast and blood cancers. About 80,000 people with Medicare Part D coverage used them in a one-year ...
Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback